Moderate riskFDA DrugClass II

Direct Rx Duloxetine D/R recalled for N-nitroso impurity above FDA limit

Direct Rx's packaged Duloxetine D/R 30 mg capsules contain levels of N-nitroso-duloxetine, a potentially harmful impurity, above FDA's recommended limit. This is a manufacturing quality issue affecting specific lots distributed nationwide.

From the FDA notice · Read the official notice ↗

What to do

  1. Check your Duloxetine D/R bottle for lot numbers 09JA2530, 31JA2507, 09DE2412, 09JA2528, or 29JA2511 (all expire 04/30/2027)
  2. Contact your pharmacist or doctor if you have one of the affected lots
  3. Do not stop taking your medication without talking to your doctor first

Is yours affected?

Compare your label or packaging with the recalled product.

Product
DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.
Sold in
Nationwide
Made for
Adults

Details

Units affected
263 Bottles
Illnesses reported
None reported
Manufactured in
94 Worldwide Dr, N/A, Dawsonville, GA, United States
Classification
Class II
Recall number
D-0617-2026

In the FDA's words

Description
DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx. CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit Lot: a) 09JA2530, 31JA2507, expires: 04/30/2027; b) Lot: 09DE2412, 09JA2528, 29JA2511, expires: 04/30/2027. Distribution: U.S. Nationwide Affected quantity: 263 Bottles
Hazard
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

More from Direct Rx

Related topics

Industrial chemicalsOtherDrugsSold nationwideMore from FDA Drug